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Abstract  
Chemoradiotherapy is standard treatment for localized aggressive
 
lymphoma (Miller et al., 
NEJM, 1998). Because previously published
 
series were heterogeneous with regard to prognostic 
factors
 
such as age, we aimed to determine the optimal therapy for elderly
 
patients with low risk 
localized lymphoma. From March 1993 to
 
June 2002, 576 patients (pts) over 60y of age with 
aggressive
 
lymphoma (WF histology: F, G, H or Kiel anaplastic) and without
 
any adverse factor 
of the age-adjusted International Pronostic
 
Index were randomly assigned to a 
chemoradiotherapy arm (299
 
pts) consisting of 4 cycles of CHOP (doxorubicin 50 mg/m2 d1,
 
cyclophosphamide 750 mg/m2 d1, vincristine 1.4 mg/m2 [up to
 
2 mg] d1, prednisone 60 mg/m2 
d1-5) given every 3 weeks followed
 
by 40 Gy involved-field radiotherapy or to a chemotherapy-
alone
 
arm (277 pts) consisting of 4 cycles of CHOP given every 3 weeks.
 
Randomization was 
stratified according to center and the presence
 
of bulky disease ( 10 cm). Principal characteristics 
were: median
 
age, 68y; male gender, 52%; stage I, 63%; bulky disease, 8%;
 
extranodal 
involvement, 56%; diffuse large B-cell histology,
 
80%. Complete response at the end of 
treatment was similar in
 
both groups (89% and 90 % respectively). Treatment-related death
 
occurred in 1% of pts in each group. On an intent-to-treat basis
 
and with a median follow-up of 
6.8y, event-free survival (EFS)
 
and overall survival (OS) did not differ significantly between
 
the 
two treatment groups (p= 0.7 and p = 0.6, respectively).
 
5y-EFS rates were 68% for pts treated 
with chemotherapy alone
 
as compared to 66% for those receiving chemoradiotherapy; 5y-OS
 
rates were 72% and 68% respectively. 66%, of deaths resulted
 
from lymphoma progression. In 
the subgroup of 247 pts over 70y
 
of age, the 5y-OS was higher in those treated by chemotherapy
 
alone (70% as compared to 58%) but this trend did not reach
 
significance (p=0.1). In a 
multivariate analysis of the 576
 
pts, EFS and OS were affected by stage II (p<0.0001), male
 
gender (p=0.02), not by tumor bulk.
 
 
Conclusion: mature data of the LNH93-4 trial indicate that CHOP
 
plus radiotherapy does not 
provide any advantage over CHOP alone
 
for the treatment of low risk localized aggressive 
lymphoma
 
in elderly pts. To note, although the majority of patients had
 
stage I disease, local 
control by irradiation did not decrease
 
the overall relapse rate. A similar conclusion was recently
 
reached in young adult pts treated by chemotherapy alone (Reyes
 
et al, NEMJ 2005). Taking 
these results together, we consider
 
that local irradiation following chemotherapy has no role in
 
the treatment of pts with low risk localized aggressive lymphoma.
 
On the basis of its previous 
published results (Coiffier et
 
al, NEJM, 2002), the GELA recommends to treat such elderly pts
 
with rituximab plus CHOP.
 
 
 
